{"ticker": {"uuid": "4f20926e-8b28-49c9-b316-db0b0d55343a", "symbol": "GRFS", "name": "Grifols SA ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Grifols stock steadies on its plasma business model", "summary": "Grifols' stock performance is primarily driven by its plasma-derived therapies business model, focusing on immunoglobulins, albumin, and other specialty medicines. The company's success relies on efficient plasma collection, fractionation, and long-cycle production, rather than s", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-steadies-on-its-plasma-business-model/69759903", "source_name": "ad-hoc-news.de", "published_at": "2026-07-13T11:10:36", "published_display": "13 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: Exploring a Potential 49.45% Upside for Healthcare Investors", "summary": "Grifols, S.A. (GRFS), a Spanish pharmaceutical company specializing in plasma-derived medicines, is showing a potential upside of 49.45% despite recent revenue declines. Trading at $7.27 USD with a market capitalization of $4.95 billion, the stock has a low forward P/E ratio of 5", "url": "https://www.directorstalkinterviews.com/grifols-s-a-grfs-stock-analysis-exploring-a-potential-49-45-upside-for-healthcare-investors/4121256182", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:09", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock holds steady as investors weigh the business mix", "summary": "Grifols, a Spanish company specializing in plasma-derived medicines, diagnostics, and hospital products, is maintaining a steady stock performance as investors evaluate its diverse business model. The company's focus on therapies from human plasma provides a defensive profile, th", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-holds-steady-as-investors-weigh-the-business-mix/69748923", "source_name": "ad-hoc-news.de", "published_at": "2026-07-12T01:39:29", "published_display": "12 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock reflects a complex plasma business amid global healthcare demand", "summary": "Grifols S.A. stock offers exposure to the specialized global market for plasma-derived medicines, built on a network of plasma collection centers, advanced fractionation plants, and a diverse portfolio of treatments for chronic and acute conditions. The company's business model r", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-reflects-a-complex-plasma-business-amid-global-healthcare/69741558", "source_name": "ad-hoc-news.de", "published_at": "2026-07-11T08:23:00", "published_display": "11 Jul 2026 08:23", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks", "summary": "This article provides a list of actively and passively managed ETFs that hold Grifols, S.A. Sponsored ADR Class B stocks. The ETFs are sorted by their market value of Grifols holdings and include details such as issuer, management style, focus, expense ratio, assets under managem", "url": "https://www.tradingview.com/symbols/LS-A1J1E2/etfs/", "source_name": "TradingView", "published_at": "2026-07-10T17:10:38", "published_display": "10 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock holds steady as plasma specialist refines its business model", "summary": "Grifols stock shows a company transforming as the plasma specialist prioritizes debt reduction and operational improvements to fuel long-term expansion. The company, a global leader in plasma-derived medicines, is focusing on financial discipline, portfolio optimization, and effi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-holds-steady-as-plasma-specialist-refines-its-business-model/69737664", "source_name": "Ad Hoc News", "published_at": "2026-07-10T12:41:13", "published_display": "10 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols SA outlines plasma strategy as investors weigh long-term growth", "summary": "Grifols SA, a global leader in plasma-derived medicines, is focusing on refining its collection and manufacturing operations while addressing investor concerns about balance sheet discipline and demand for immunology treatments. The company's strategy involves improving efficienc", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-sa-outlines-plasma-strategy-as-investors-weigh-long-term-growth/69731948", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T14:31:00", "published_display": "09 Jul 2026 14:31", "sentiment": "positive", "sentiment_pct": 71, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols navigates plasma demand and debt strategy as global healthcare needs grow", "summary": "Grifols S.A. is managing the complex interplay of plasma supply, debt reduction, and regulatory oversight, crucial for providing therapies for immune and neurological conditions worldwide. The company is focused on strengthening investor confidence through transparent communicati", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-navigates-plasma-demand-and-debt-strategy-as-global-healthcare/69730824", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T10:10:57", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "G0FB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides forecast and price target information for Grifols, S.A. Sponsored ADR Class B (G0FB). It indicates a price target of 12.32 based on analyst forecasts and includes sections for analyst ratings, EPS, and revenue metrics.", "url": "https://www.tradingview.com/symbols/GETTEX-G0FB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-08T23:09:20", "published_display": "08 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols strengthens its plasma-based therapies. Investors watch the long-term growth story", "summary": "Grifols S.A. is expanding its global plasma business and specialty therapies, focusing on plasma-derived medicines and diagnostics. The company's strategy involves investments in plasma collection, diversified diagnostics, and bioscience services, aiming for long-term growth whil", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-strengthens-its-plasma-based-therapies-investors-watch-the/69720139", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T08:06:00", "published_display": "08 Jul 2026 08:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Grifols, S.A. Class A \u2013 BME:GRF", "summary": "This article displays the \"Price to earnings forward\" financial metric for Grifols, S.A. Class A (BME:GRF) on TradingView. It shows that there are no trades and the market is closed for this specific data point, which is made by humans. The content is primarily a data placeholder", "url": "https://www.tradingview.com/symbols/BME-GRF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T07:13:24", "published_display": "07 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Grifols, S.A. Class A Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Grifols, S.A. Class A stocks. It provides a detailed table including each fund's market value, weight of Grifols stock, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume", "url": "https://www.tradingview.com/symbols/GETTEX-OZTA/etfs/", "source_name": "TradingView", "published_at": "2026-07-06T11:44:46", "published_display": "06 Jul 2026 11:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: A 51.75% Upside Potential In The Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQVFpKd2JuT1pfeWVTN2MyMEVEdmFEblNoUzhRSjJJMkpWaWZXSnJZaFllVzZjYWItV04ybVRPcUVCUDFQTTBmY2VBQ21QNVpSYUFiTGhob3I3M0gwMDBKOG1YWTFFUFhhUGNuNUdnU3picXNDQW0xQUtTandfVUd3Q2IyVWR2SXpsTHdSOC1FS3ZsZHQ1ZFE1SHE0WXhlNC1xaGhiVHAtSV80TUhpZmdMMm1WWTVwa0FfVUlLdm1uaDF3RmVMZ0lUcUtQOUI?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:24:12+00:00", "published_display": "06 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Grifols, S.A. Class A \u2013 VIE:GRF", "summary": "This article provides the \"Price to earnings forward\" metric for Grifols, S.A. Class A (VIE:GRF) on the Vienna Stock Exchange. It indicates that the market was closed with no trades recorded for this particular metric. The content primarily focuses on financial data for the pharm", "url": "https://www.tradingview.com/symbols/VIE-GRF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T02:40:41", "published_display": "06 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols S.A. highlights plasma leadership as investors assess long-term strategy", "summary": "Grifols S.A. is maintaining its strong position in the global plasma-based medicines market, with investors closely evaluating its long-term strategy and financial health. The company, known for its extensive plasma collection network and complex fractionation facilities, focuses", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-s-a-highlights-plasma-leadership-as-investors-assess-long-term/69694027", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T07:39:10", "published_display": "05 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2ABZN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Grifols, S.A. Pref Class B (A2ABZN) stock, outlining analysts' expectations for its future price. It also covers the stock's current price, historical performance, market capitalization, and financial data including revenue, n", "url": "https://www.tradingview.com/symbols/LSX-A2ABZN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-04T21:10:18", "published_display": "04 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock holds its line. Investors watch the next filing.", "summary": "Grifols stock is holding steady, with investors focusing on the company's business fundamentals and upcoming filings rather than new headlines. The Spanish plasma products group, Grifols S.A. (ISIN ES0171996087), operates a plasma collection and processing model, making cash gene", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-holds-its-line-investors-watch-the-next-filing/69687340", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-04T11:09:27", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Short Interest", "summary": "This article provides a detailed overview of Grifols SA ADR (GRFS) stock, focusing on its short interest and various financial metrics. It includes data on market capitalization, income, sales, dividends, P/E ratio, EPS growth, insider and institutional ownership, profitability m", "url": "https://finviz.com/stock?t=GRFS&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-04T10:09:27", "published_display": "04 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Volatility & Greeks", "summary": "This article provides a comprehensive financial overview of Grifols SA ADR (GRFS), detailing its stock performance, volatility, and key financial ratios. It includes data on market capitalization, income, sales, dividend information, and analyst recommendations. The report also h", "url": "https://finviz.com/stock?t=GRFS&ty=ocv&ta=1&p=w&ov=chain_strike&s=17", "source_name": "Finviz", "published_at": "2026-07-03T23:40:46", "published_display": "03 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols steady as plasma business underpins long-term growth", "summary": "Grifols S.A. relies on its global plasma-derivatives franchise and diversified product portfolio for long-term growth, despite ongoing balance sheet priorities and evolving market regulations. The company's core business, plasma-derived therapies, drives most revenue and benefits", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-steady-as-plasma-business-underpins-long-term-growth/69681408", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:40:46", "published_display": "03 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Latest SEC Filings", "summary": "This article provides comprehensive financial data and performance metrics for Grifols SA ADR (GRFS). It covers key financial figures like market cap, income, sales, and various ratios, along with stock performance metrics, insider ownership, analyst recommendations, and recent S", "url": "https://finviz.com/stock?t=GRFS&p=d&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-03T14:39:10", "published_display": "03 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols focuses on plasma-based therapies as investors assess long-term growth", "summary": "Grifols S.A. is a global healthcare group specializing in plasma-derived medicines, with a business model centered on a stable network of plasma donation centers, strict quality controls, and compliance. The company's long-term growth is driven by increasing demand for specialty ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-focuses-on-plasma-based-therapies-as-investors-assess-long-term/69676914", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-02T21:13:11", "published_display": "02 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Options", "summary": "This article provides a detailed financial overview of Grifols SA (GRFS) ADR, including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists performance metrics, insider ownership, institutional ownership, and short interest da", "url": "https://finviz.com/stock?t=GRFS&ty=oc&ta=1&p=w&ov=list_date&e=2026-11-20", "source_name": "Finviz", "published_at": "2026-07-02T18:39:55", "published_display": "02 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Grifols SA ADR (GRFS), including key financial metrics, performance indicators, and analyst target prices. It highlights the company's current stock price, dividend information, various valuation ratios, and per", "url": "https://finviz.com/stock?t=GRFS&ta=1&p=d&ty=fc&b=1", "source_name": "Finviz", "published_at": "2026-07-02T14:39:10", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Grifols, S.A. Class A \u2013 BX:OZTA", "summary": "This article displays financial data for Grifols, S.A. Class A (BX:OZTA), specifically its price-to-earnings forward ratio. The content primarily consists of navigation and technical details from the TradingView platform, with limited substantive financial information presented i", "url": "https://www.tradingview.com/symbols/BX-OZTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T11:10:44", "published_display": "29 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "G0F Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This TradingView page provides forecast information, price targets, and analyst ratings for Grifols, S.A. Sponsored ADR Class A (G0F) on the Munich Stock Exchange. It includes sections for actuals and estimates for EPS and revenue, along with a disclaimer stating it is not invest", "url": "https://www.tradingview.com/symbols/MUN-G0F/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T10:39:18", "published_display": "28 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Grifols, S.A. Class A \u2013 EUROTLX:4GRF", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Grifols, S.A. Class A (4GRF) on the EUROTLX exchange, as presented on TradingView. It indicates that no specific value or change information is currently available for this metric. The content largely compri", "url": "https://www.tradingview.com/symbols/EUROTLX-4GRF/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:57", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides a forecast and price target for Grifols, S.A. (GRFS) for the year 2027. It indicates a price target of 14.43 based on one analyst's forecast and also includes information on analyst ratings, EPS, and revenue metrics.", "url": "https://www.tradingview.com/symbols/BOATS-GRFS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T12:10:58", "published_display": "27 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. Class A Actuals & Estimates (EUROTLX:4GRF)", "summary": "This article provides financial actuals and estimates for Grifols, S.A. Class A (4GRF) traded on EUROTLX, covering income statement, balance sheet, and cash flow. It includes current stock price, historical performance, analyst forecasts, and upcoming earnings dates. The company'", "url": "https://www.tradingview.com/symbols/EUROTLX-4GRF/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T11:39:18", "published_display": "27 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. Class A Actuals & Estimates (BME:GRF)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPNXNERi1MbERKNDVGeDlsLW5HbzFOdkJpZlZybDNyQ24tTVdjS3Q5ZHFnanFmVXZNT1JkWjQwYXcwS3VyLXBjUmVVVkYtVzk5ZDlnSW40dTc3ZHZXam5VcGI4RnAyMUx0cG5qQ1NuSDlDNGx5X0NGb082ODc5ZHcwUQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T01:21:59+00:00", "published_display": "27 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/grifols-grfs-launches-fesilty-u-165231770.html", "source_name": "Insider Monkey", "published_at": "2026-06-19T16:52:31+00:00", "published_display": "19 Jun 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols SA (GRFS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9lNHFyTW9DbS1KYjE2N2FiVU9MclNQTks1NlZPaUx6WnN4TFMtQVlyVUVucjduN3JPT193MDV5NTF5eUlIQ2xPZl9NZk44aEM2Q2VmbGg4b01rZ1doTk1FNE40WGdCNmVNTnh2ZUwtRFEwNFRHUExEWg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T13:20:03+00:00", "published_display": "17 Jun 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols Launches Fesilty Blood Clotting Concentrate in US", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grifols-launches-fesilty-blood-clotting-123304613.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:33:04+00:00", "published_display": "15 Jun 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols Launches FESILTY\u2122 (fibrinogen, human-chmt) in the U.S.", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grifols-launches-fesilty-fibrinogen-human-120000074.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:00:00+00:00", "published_display": "15 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: Exploring a 42% Upside Potential in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQZ1ZSbnhOYWVKWTNRdG5RZGhRRnBkeTNyTlFMY2ltTWpGWDF1OTFPYVppTnp6SmxTTkJJbFFJdGJ3RjNGR3ZhMXB4Q3RUamJ5Vl9kR0s2cVBxeTB1NlZ1QlpWZDdGV3pZMDhBRUd5QnpEazRHang4Qm1zeG42XzFpRXpTc1I4SnBTZTJ5VmVoTDM1UWR3aFNrR2h5Z2lueWhPdkFxc1NkNUFwbEM4YlZMM2Y0eHlXVHlKZFg2aFFodW5vX2FwZmJBQmNxV3FlOVd1SGhfanNR?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst (NASDAQ:GRFS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNVEVBU052NVJ1ZE9WLTVCTHcxR0Fob2FFWER5Vkg0Tl9ybUVXVEhUVlVNSTFwT3A3ZVcxNXFodm9nU2FESS04Qm4xcGxWZ0hVREh4dVc1WjBvOU9keGxreWF1bWFaNlE2QTV0RzNpdWlQRXUzZWNEbXVPNGJKdVotUTFlMmt1U1hOX2diTVVlaHh0WEdBTzBvRTVxM0ViUWJ5aWVIQjFmUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOcGlJQXpIZ0ZXN3FKRW9yLWtCcnhWazNaQlR1MzFHZVRLb1NZMGpSQmx4NFlnQ0s3RV9mSlNCbW9MUlFpRFdrY01PbVZaV2xVNFFWWDk4WkFmVEtrM1JmYWFtaXZRWjhLOTVRWDVMOHJxN0xqMDUtbDlTWVZBMEk0bGNMbUFYQmkwaHZoeldMMnV0aHp1cnduZHJEMnhudkVlYUFxeU5B?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: Unveiling a 36% Upside Potential Amidst a Challenging Healthcare Landscape", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxPT21JY2ItUlUwV19UNHNQSExqUEhGTzcteTFCbTU3YjhhM0txcEpOZ1pKZldlMU05T0dvRVNDNWgxT2Q5UXl2LUhENEVxZGhUZFpHS0NGbXFrWTJ2d29uWUx4aUF1WWRQTExfVFlEbmliN3pnSklCTjJNQlhlOHVQQklLNlVTY3JDQ09NeTMzaEgxa0IwbThqOVQ5clNDdEJlYWVDZzVpajF1QkI4SkJ2aTktbVFJWVl6V1prSkg2NVpCZ0tzM0I4MFRNa0hVN1JOUkpScTYtdnM2N0R6NFR0QlZKaGRDcTNBOVVWZQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Grifols (BME:GRF) Investment Story Is Shifting With New Analyst Caution", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcFNmUUVmWHR3aXRCMmVrRlJxclFXdzZRRFZQZTVCVjVjMWZ5WU5WZnA4N3VFa19aemJrZEJKalVRMmJMTzF0RDg3NW9VazJSak9ldVdfUUdrbnRVNW1EN3JDWlZhTUtMNm4ybnhqWGZjWkJ6UjRpTVpHa3lGN2c0UEFZYmN3dHlsRDFuR2xKc1pMN1NkekpsZ1BoTkMtUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNd1JySEFab1BoNExrTy1yX21kaHM3YU1HQmtOb2NJSFNqYVZ1eHdQTEVVYmp2N1Awa0QydEI1M0RMME9qcjQxX1VTTFlxT2dQRzBGTTFBMnFPWU1sb0g4SHhxLVZna0FzOThuZWZicVNXaGpmM3VSWGd4Q2lab0JUWkg5QmJoeWRjTnNFaEZNaGhHLVVDWEFsanVYcjluc1hHZ0NKMnVyR0FrU2xDdVJOVG9xajZHdTdaR25Ub1dGcWVJU2RFLTF2MQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols (BME:GRF) Valuation Check After Mixed Short And Long Term Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOd3NncXVJUWVITjNRSC1BbUtOOHc0dE9aUVVOQ1dDYlNjQ1lJWFpQM3JRT0t0a0dlYkRHclNRQ0p3dlN0ZHo4ZlNaUFh5TXhIVVg3TXZMZE4xcU5WbXBnVmFCZGUxcDNRWS0xeHVtdUI2WS1wSVRWZDJmTHVZZmZzV0hMR1h3dzhQbUFQdXRxdEhvd0pONl9GYkxtZlk?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:GIKLY) 2026-05-07", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZ3FYV05fT0c0M0dWUlBYNVc4akxDVzkwZ05HdjYzTi1mMHZFY1BNLXYzQVg0RHpORGVKWC1wZE9na2VGTjY1UFQxZFU5eUNldHpYbHRsOHBrWkg3T1l2UEF5YUF1TXFyejBMQVVhdlhudGRXM1p2ZUo1ZV9LaTFwa0tzSGNFVTZ4MndycGMzcDZUcXN4WU1oZmlyQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols (GRFS) Unveils AI-Driven Data for Early Parkinson\u2019s Disease Detection", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPTVdIVGl1LXQ2X1YwQUo4VV9rTGJ4WUwtT29fTEo0Q0ZfR3IwRGFRU0dFMEpOMTdqNDdGajJJMmt4TGVlT1Fvak1mMVc5c3VPaUhHTzZERV9DVDF1OU9UOS1xMGc2OGNNck5rRmgtSDhnRXp6ZnUyZjJtd2xrblJJN1FUajhnT1Q4Y1RMTnBlX00xRndnZ0lYUnFOMTFhMW1k?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNaHgtSEcxVFdLOEhscXJmeGhXYWVWLUtSc2oyaGRGdDBFSmJiY1FaQWNhQkNGRVF0dmEtcUxxU2FjcEpBZkRsalhhVFdlWGZLMG94RURwanNqa3RKWEEwejRWaDY0OGROeFlySmg0Njc0d2JtQUdVRXZVWU01VXFPZFJZRFBadlpCNVpWV015dGZNUG0xX01fSlVBNWFXYi1rWmE5VXVwaGcxM25DX3c?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols facing restrictions in Canada after plasma donor deaths", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPZVBVekFUdmFtZ1l1UG1mX2pZNXFEUHFsY0pKRmJHNDV3SDZpbVJHMHY3WVhQeEg5QzdKRnktVFE1WTBtN3RzRDA3NWtlQkU4aEhKUFRnWDU5RFFFbjJqY1A0eFFIdVJHVFVaOHE1eDNmTFBULUxZUWhxTTdWYzNaR0xfekdpeGJjSG5TU212alFIOHFDUGp3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols approves IPO of its US biopharma business", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPYjRLZ1MzTUZGV1FCVWxxclprSWdrd1EtNVJIeEhlLUJuMERUYlNaZ1NWRS03XzhJQnVvY3ZzU0tKeGdfNDlOR1V5TlgwMFQzZzJzWFZxTjFzcVQwRDY1LTlHcURLbkVWNDdBN3hVWXVLQWt6UllOVktuRzkwdVF2OFh3ekFkM1R1VEh1bDk5LUNpYzRULXpTVVV0ZGp3T1VFeGc4SA?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQWjVfVWtRbW91aW80MW9BeEtHeXVIR2tLVEl1MG5iTFByRlcyU3BTSW1YZi1aXzNKSUpMOWMtWVlpaXNrZTd5T0RZcy1PRlZ0ZXNCNUJwd1JRekFDc2JDSFVrOThsQm5QeUZpYVpHQng0NkhoQ2pOSkdmcU1ZcC1BUTkxYUE3RmM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols S.A. (GRFS) Releases Q4 2025 Earnings: Revenue Up Strongly but EPS and Cash Flow Slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNVDN0TDZRVVdPWlpRSFdGVGZ4SDg0V3JmeHhTdHczRldsQ0txMHR5X0FZTlRRdGVhRkFCbVVYYUJBOUhwNDF3UU9RTHBnLXR3UWEzNmt4aERBak54amQtN1NfWmVhaUtxZTZ6MFA3YjdFTTA0YmRpcGtsRmJJbHFDTkItVTlsY3I2NWlfeF90TVFmcldGbkVSQjVWY0EtM2J4cWdVSExZVjdPSndEbFRLTW8yMkpXVGV0RUFYbXowdXhPeXg2Tm90S1NLMlIyUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Grifols stock steadies on its plasma business model", "summary": "Grifols' stock performance is primarily driven by its plasma-derived therapies business model, focusing on immunoglobulins, albumin, and other specialty medicines. The company's success relies on efficient plasma collection, fractionation, and long-cycle production, rather than s", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-steadies-on-its-plasma-business-model/69759903", "source_name": "ad-hoc-news.de", "published_at": "2026-07-13T11:10:36", "published_display": "13 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: Exploring a Potential 49.45% Upside for Healthcare Investors", "summary": "Grifols, S.A. (GRFS), a Spanish pharmaceutical company specializing in plasma-derived medicines, is showing a potential upside of 49.45% despite recent revenue declines. Trading at $7.27 USD with a market capitalization of $4.95 billion, the stock has a low forward P/E ratio of 5", "url": "https://www.directorstalkinterviews.com/grifols-s-a-grfs-stock-analysis-exploring-a-potential-49-45-upside-for-healthcare-investors/4121256182", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:09", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock holds steady as investors weigh the business mix", "summary": "Grifols, a Spanish company specializing in plasma-derived medicines, diagnostics, and hospital products, is maintaining a steady stock performance as investors evaluate its diverse business model. The company's focus on therapies from human plasma provides a defensive profile, th", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-holds-steady-as-investors-weigh-the-business-mix/69748923", "source_name": "ad-hoc-news.de", "published_at": "2026-07-12T01:39:29", "published_display": "12 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock reflects a complex plasma business amid global healthcare demand", "summary": "Grifols S.A. stock offers exposure to the specialized global market for plasma-derived medicines, built on a network of plasma collection centers, advanced fractionation plants, and a diverse portfolio of treatments for chronic and acute conditions. The company's business model r", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-reflects-a-complex-plasma-business-amid-global-healthcare/69741558", "source_name": "ad-hoc-news.de", "published_at": "2026-07-11T08:23:00", "published_display": "11 Jul 2026 08:23", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks", "summary": "This article provides a list of actively and passively managed ETFs that hold Grifols, S.A. Sponsored ADR Class B stocks. The ETFs are sorted by their market value of Grifols holdings and include details such as issuer, management style, focus, expense ratio, assets under managem", "url": "https://www.tradingview.com/symbols/LS-A1J1E2/etfs/", "source_name": "TradingView", "published_at": "2026-07-10T17:10:38", "published_display": "10 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock holds steady as plasma specialist refines its business model", "summary": "Grifols stock shows a company transforming as the plasma specialist prioritizes debt reduction and operational improvements to fuel long-term expansion. The company, a global leader in plasma-derived medicines, is focusing on financial discipline, portfolio optimization, and effi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-holds-steady-as-plasma-specialist-refines-its-business-model/69737664", "source_name": "Ad Hoc News", "published_at": "2026-07-10T12:41:13", "published_display": "10 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols SA outlines plasma strategy as investors weigh long-term growth", "summary": "Grifols SA, a global leader in plasma-derived medicines, is focusing on refining its collection and manufacturing operations while addressing investor concerns about balance sheet discipline and demand for immunology treatments. The company's strategy involves improving efficienc", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-sa-outlines-plasma-strategy-as-investors-weigh-long-term-growth/69731948", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T14:31:00", "published_display": "09 Jul 2026 14:31", "sentiment": "positive", "sentiment_pct": 71, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols navigates plasma demand and debt strategy as global healthcare needs grow", "summary": "Grifols S.A. is managing the complex interplay of plasma supply, debt reduction, and regulatory oversight, crucial for providing therapies for immune and neurological conditions worldwide. The company is focused on strengthening investor confidence through transparent communicati", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-navigates-plasma-demand-and-debt-strategy-as-global-healthcare/69730824", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T10:10:57", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "G0FB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides forecast and price target information for Grifols, S.A. Sponsored ADR Class B (G0FB). It indicates a price target of 12.32 based on analyst forecasts and includes sections for analyst ratings, EPS, and revenue metrics.", "url": "https://www.tradingview.com/symbols/GETTEX-G0FB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-08T23:09:20", "published_display": "08 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols strengthens its plasma-based therapies. Investors watch the long-term growth story", "summary": "Grifols S.A. is expanding its global plasma business and specialty therapies, focusing on plasma-derived medicines and diagnostics. The company's strategy involves investments in plasma collection, diversified diagnostics, and bioscience services, aiming for long-term growth whil", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-strengthens-its-plasma-based-therapies-investors-watch-the/69720139", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T08:06:00", "published_display": "08 Jul 2026 08:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Grifols, S.A. Class A \u2013 BME:GRF", "summary": "This article displays the \"Price to earnings forward\" financial metric for Grifols, S.A. Class A (BME:GRF) on TradingView. It shows that there are no trades and the market is closed for this specific data point, which is made by humans. The content is primarily a data placeholder", "url": "https://www.tradingview.com/symbols/BME-GRF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T07:13:24", "published_display": "07 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Grifols, S.A. Class A Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Grifols, S.A. Class A stocks. It provides a detailed table including each fund's market value, weight of Grifols stock, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume", "url": "https://www.tradingview.com/symbols/GETTEX-OZTA/etfs/", "source_name": "TradingView", "published_at": "2026-07-06T11:44:46", "published_display": "06 Jul 2026 11:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: A 51.75% Upside Potential In The Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQVFpKd2JuT1pfeWVTN2MyMEVEdmFEblNoUzhRSjJJMkpWaWZXSnJZaFllVzZjYWItV04ybVRPcUVCUDFQTTBmY2VBQ21QNVpSYUFiTGhob3I3M0gwMDBKOG1YWTFFUFhhUGNuNUdnU3picXNDQW0xQUtTandfVUd3Q2IyVWR2SXpsTHdSOC1FS3ZsZHQ1ZFE1SHE0WXhlNC1xaGhiVHAtSV80TUhpZmdMMm1WWTVwa0FfVUlLdm1uaDF3RmVMZ0lUcUtQOUI?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:24:12+00:00", "published_display": "06 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Grifols, S.A. Class A \u2013 VIE:GRF", "summary": "This article provides the \"Price to earnings forward\" metric for Grifols, S.A. Class A (VIE:GRF) on the Vienna Stock Exchange. It indicates that the market was closed with no trades recorded for this particular metric. The content primarily focuses on financial data for the pharm", "url": "https://www.tradingview.com/symbols/VIE-GRF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T02:40:41", "published_display": "06 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols S.A. highlights plasma leadership as investors assess long-term strategy", "summary": "Grifols S.A. is maintaining its strong position in the global plasma-based medicines market, with investors closely evaluating its long-term strategy and financial health. The company, known for its extensive plasma collection network and complex fractionation facilities, focuses", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-s-a-highlights-plasma-leadership-as-investors-assess-long-term/69694027", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T07:39:10", "published_display": "05 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2ABZN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Grifols, S.A. Pref Class B (A2ABZN) stock, outlining analysts' expectations for its future price. It also covers the stock's current price, historical performance, market capitalization, and financial data including revenue, n", "url": "https://www.tradingview.com/symbols/LSX-A2ABZN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-04T21:10:18", "published_display": "04 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols stock holds its line. Investors watch the next filing.", "summary": "Grifols stock is holding steady, with investors focusing on the company's business fundamentals and upcoming filings rather than new headlines. The Spanish plasma products group, Grifols S.A. (ISIN ES0171996087), operates a plasma collection and processing model, making cash gene", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-stock-holds-its-line-investors-watch-the-next-filing/69687340", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-04T11:09:27", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Short Interest", "summary": "This article provides a detailed overview of Grifols SA ADR (GRFS) stock, focusing on its short interest and various financial metrics. It includes data on market capitalization, income, sales, dividends, P/E ratio, EPS growth, insider and institutional ownership, profitability m", "url": "https://finviz.com/stock?t=GRFS&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-04T10:09:27", "published_display": "04 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Volatility & Greeks", "summary": "This article provides a comprehensive financial overview of Grifols SA ADR (GRFS), detailing its stock performance, volatility, and key financial ratios. It includes data on market capitalization, income, sales, dividend information, and analyst recommendations. The report also h", "url": "https://finviz.com/stock?t=GRFS&ty=ocv&ta=1&p=w&ov=chain_strike&s=17", "source_name": "Finviz", "published_at": "2026-07-03T23:40:46", "published_display": "03 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols steady as plasma business underpins long-term growth", "summary": "Grifols S.A. relies on its global plasma-derivatives franchise and diversified product portfolio for long-term growth, despite ongoing balance sheet priorities and evolving market regulations. The company's core business, plasma-derived therapies, drives most revenue and benefits", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-steady-as-plasma-business-underpins-long-term-growth/69681408", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:40:46", "published_display": "03 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Latest SEC Filings", "summary": "This article provides comprehensive financial data and performance metrics for Grifols SA ADR (GRFS). It covers key financial figures like market cap, income, sales, and various ratios, along with stock performance metrics, insider ownership, analyst recommendations, and recent S", "url": "https://finviz.com/stock?t=GRFS&p=d&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-03T14:39:10", "published_display": "03 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols focuses on plasma-based therapies as investors assess long-term growth", "summary": "Grifols S.A. is a global healthcare group specializing in plasma-derived medicines, with a business model centered on a stable network of plasma donation centers, strict quality controls, and compliance. The company's long-term growth is driven by increasing demand for specialty ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/grifols-focuses-on-plasma-based-therapies-as-investors-assess-long-term/69676914", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-02T21:13:11", "published_display": "02 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Options", "summary": "This article provides a detailed financial overview of Grifols SA (GRFS) ADR, including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists performance metrics, insider ownership, institutional ownership, and short interest da", "url": "https://finviz.com/stock?t=GRFS&ty=oc&ta=1&p=w&ov=list_date&e=2026-11-20", "source_name": "Finviz", "published_at": "2026-07-02T18:39:55", "published_display": "02 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS - Grifols SA ADR Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Grifols SA ADR (GRFS), including key financial metrics, performance indicators, and analyst target prices. It highlights the company's current stock price, dividend information, various valuation ratios, and per", "url": "https://finviz.com/stock?t=GRFS&ta=1&p=d&ty=fc&b=1", "source_name": "Finviz", "published_at": "2026-07-02T14:39:10", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Grifols, S.A. Class A \u2013 BX:OZTA", "summary": "This article displays financial data for Grifols, S.A. Class A (BX:OZTA), specifically its price-to-earnings forward ratio. The content primarily consists of navigation and technical details from the TradingView platform, with limited substantive financial information presented i", "url": "https://www.tradingview.com/symbols/BX-OZTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T11:10:44", "published_display": "29 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "G0F Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This TradingView page provides forecast information, price targets, and analyst ratings for Grifols, S.A. Sponsored ADR Class A (G0F) on the Munich Stock Exchange. It includes sections for actuals and estimates for EPS and revenue, along with a disclaimer stating it is not invest", "url": "https://www.tradingview.com/symbols/MUN-G0F/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T10:39:18", "published_display": "28 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Grifols, S.A. Class A \u2013 EUROTLX:4GRF", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Grifols, S.A. Class A (4GRF) on the EUROTLX exchange, as presented on TradingView. It indicates that no specific value or change information is currently available for this metric. The content largely compri", "url": "https://www.tradingview.com/symbols/EUROTLX-4GRF/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:57", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRFS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides a forecast and price target for Grifols, S.A. (GRFS) for the year 2027. It indicates a price target of 14.43 based on one analyst's forecast and also includes information on analyst ratings, EPS, and revenue metrics.", "url": "https://www.tradingview.com/symbols/BOATS-GRFS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T12:10:58", "published_display": "27 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. Class A Actuals & Estimates (EUROTLX:4GRF)", "summary": "This article provides financial actuals and estimates for Grifols, S.A. Class A (4GRF) traded on EUROTLX, covering income statement, balance sheet, and cash flow. It includes current stock price, historical performance, analyst forecasts, and upcoming earnings dates. The company'", "url": "https://www.tradingview.com/symbols/EUROTLX-4GRF/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T11:39:18", "published_display": "27 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. Class A Actuals & Estimates (BME:GRF)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPNXNERi1MbERKNDVGeDlsLW5HbzFOdkJpZlZybDNyQ24tTVdjS3Q5ZHFnanFmVXZNT1JkWjQwYXcwS3VyLXBjUmVVVkYtVzk5ZDlnSW40dTc3ZHZXam5VcGI4RnAyMUx0cG5qQ1NuSDlDNGx5X0NGb082ODc5ZHcwUQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T01:21:59+00:00", "published_display": "27 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/grifols-grfs-launches-fesilty-u-165231770.html", "source_name": "Insider Monkey", "published_at": "2026-06-19T16:52:31+00:00", "published_display": "19 Jun 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols SA (GRFS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9lNHFyTW9DbS1KYjE2N2FiVU9MclNQTks1NlZPaUx6WnN4TFMtQVlyVUVucjduN3JPT193MDV5NTF5eUlIQ2xPZl9NZk44aEM2Q2VmbGg4b01rZ1doTk1FNE40WGdCNmVNTnh2ZUwtRFEwNFRHUExEWg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T13:20:03+00:00", "published_display": "17 Jun 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols Launches Fesilty Blood Clotting Concentrate in US", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grifols-launches-fesilty-blood-clotting-123304613.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:33:04+00:00", "published_display": "15 Jun 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols Launches FESILTY\u2122 (fibrinogen, human-chmt) in the U.S.", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grifols-launches-fesilty-fibrinogen-human-120000074.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:00:00+00:00", "published_display": "15 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: Exploring a 42% Upside Potential in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQZ1ZSbnhOYWVKWTNRdG5RZGhRRnBkeTNyTlFMY2ltTWpGWDF1OTFPYVppTnp6SmxTTkJJbFFJdGJ3RjNGR3ZhMXB4Q3RUamJ5Vl9kR0s2cVBxeTB1NlZ1QlpWZDdGV3pZMDhBRUd5QnpEazRHang4Qm1zeG42XzFpRXpTc1I4SnBTZTJ5VmVoTDM1UWR3aFNrR2h5Z2lueWhPdkFxc1NkNUFwbEM4YlZMM2Y0eHlXVHlKZFg2aFFodW5vX2FwZmJBQmNxV3FlOVd1SGhfanNR?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst (NASDAQ:GRFS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNVEVBU052NVJ1ZE9WLTVCTHcxR0Fob2FFWER5Vkg0Tl9ybUVXVEhUVlVNSTFwT3A3ZVcxNXFodm9nU2FESS04Qm4xcGxWZ0hVREh4dVc1WjBvOU9keGxreWF1bWFaNlE2QTV0RzNpdWlQRXUzZWNEbXVPNGJKdVotUTFlMmt1U1hOX2diTVVlaHh0WEdBTzBvRTVxM0ViUWJ5aWVIQjFmUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOcGlJQXpIZ0ZXN3FKRW9yLWtCcnhWazNaQlR1MzFHZVRLb1NZMGpSQmx4NFlnQ0s3RV9mSlNCbW9MUlFpRFdrY01PbVZaV2xVNFFWWDk4WkFmVEtrM1JmYWFtaXZRWjhLOTVRWDVMOHJxN0xqMDUtbDlTWVZBMEk0bGNMbUFYQmkwaHZoeldMMnV0aHp1cnduZHJEMnhudkVlYUFxeU5B?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. (GRFS) Stock Analysis: Unveiling a 36% Upside Potential Amidst a Challenging Healthcare Landscape", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxPT21JY2ItUlUwV19UNHNQSExqUEhGTzcteTFCbTU3YjhhM0txcEpOZ1pKZldlMU05T0dvRVNDNWgxT2Q5UXl2LUhENEVxZGhUZFpHS0NGbXFrWTJ2d29uWUx4aUF1WWRQTExfVFlEbmliN3pnSklCTjJNQlhlOHVQQklLNlVTY3JDQ09NeTMzaEgxa0IwbThqOVQ5clNDdEJlYWVDZzVpajF1QkI4SkJ2aTktbVFJWVl6V1prSkg2NVpCZ0tzM0I4MFRNa0hVN1JOUkpScTYtdnM2N0R6NFR0QlZKaGRDcTNBOVVWZQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Grifols (BME:GRF) Investment Story Is Shifting With New Analyst Caution", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcFNmUUVmWHR3aXRCMmVrRlJxclFXdzZRRFZQZTVCVjVjMWZ5WU5WZnA4N3VFa19aemJrZEJKalVRMmJMTzF0RDg3NW9VazJSak9ldVdfUUdrbnRVNW1EN3JDWlZhTUtMNm4ybnhqWGZjWkJ6UjRpTVpHa3lGN2c0UEFZYmN3dHlsRDFuR2xKc1pMN1NkekpsZ1BoTkMtUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNd1JySEFab1BoNExrTy1yX21kaHM3YU1HQmtOb2NJSFNqYVZ1eHdQTEVVYmp2N1Awa0QydEI1M0RMME9qcjQxX1VTTFlxT2dQRzBGTTFBMnFPWU1sb0g4SHhxLVZna0FzOThuZWZicVNXaGpmM3VSWGd4Q2lab0JUWkg5QmJoeWRjTnNFaEZNaGhHLVVDWEFsanVYcjluc1hHZ0NKMnVyR0FrU2xDdVJOVG9xajZHdTdaR25Ub1dGcWVJU2RFLTF2MQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols (BME:GRF) Valuation Check After Mixed Short And Long Term Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOd3NncXVJUWVITjNRSC1BbUtOOHc0dE9aUVVOQ1dDYlNjQ1lJWFpQM3JRT0t0a0dlYkRHclNRQ0p3dlN0ZHo4ZlNaUFh5TXhIVVg3TXZMZE4xcU5WbXBnVmFCZGUxcDNRWS0xeHVtdUI2WS1wSVRWZDJmTHVZZmZzV0hMR1h3dzhQbUFQdXRxdEhvd0pONl9GYkxtZlk?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols, S.A. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:GIKLY) 2026-05-07", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZ3FYV05fT0c0M0dWUlBYNVc4akxDVzkwZ05HdjYzTi1mMHZFY1BNLXYzQVg0RHpORGVKWC1wZE9na2VGTjY1UFQxZFU5eUNldHpYbHRsOHBrWkg3T1l2UEF5YUF1TXFyejBMQVVhdlhudGRXM1p2ZUo1ZV9LaTFwa0tzSGNFVTZ4MndycGMzcDZUcXN4WU1oZmlyQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols (GRFS) Unveils AI-Driven Data for Early Parkinson\u2019s Disease Detection", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPTVdIVGl1LXQ2X1YwQUo4VV9rTGJ4WUwtT29fTEo0Q0ZfR3IwRGFRU0dFMEpOMTdqNDdGajJJMmt4TGVlT1Fvak1mMVc5c3VPaUhHTzZERV9DVDF1OU9UOS1xMGc2OGNNck5rRmgtSDhnRXp6ZnUyZjJtd2xrblJJN1FUajhnT1Q4Y1RMTnBlX00xRndnZ0lYUnFOMTFhMW1k?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNaHgtSEcxVFdLOEhscXJmeGhXYWVWLUtSc2oyaGRGdDBFSmJiY1FaQWNhQkNGRVF0dmEtcUxxU2FjcEpBZkRsalhhVFdlWGZLMG94RURwanNqa3RKWEEwejRWaDY0OGROeFlySmg0Njc0d2JtQUdVRXZVWU01VXFPZFJZRFBadlpCNVpWV015dGZNUG0xX01fSlVBNWFXYi1rWmE5VXVwaGcxM25DX3c?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols facing restrictions in Canada after plasma donor deaths", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPZVBVekFUdmFtZ1l1UG1mX2pZNXFEUHFsY0pKRmJHNDV3SDZpbVJHMHY3WVhQeEg5QzdKRnktVFE1WTBtN3RzRDA3NWtlQkU4aEhKUFRnWDU5RFFFbjJqY1A0eFFIdVJHVFVaOHE1eDNmTFBULUxZUWhxTTdWYzNaR0xfekdpeGJjSG5TU212alFIOHFDUGp3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols approves IPO of its US biopharma business", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPYjRLZ1MzTUZGV1FCVWxxclprSWdrd1EtNVJIeEhlLUJuMERUYlNaZ1NWRS03XzhJQnVvY3ZzU0tKeGdfNDlOR1V5TlgwMFQzZzJzWFZxTjFzcVQwRDY1LTlHcURLbkVWNDdBN3hVWXVLQWt6UllOVktuRzkwdVF2OFh3ekFkM1R1VEh1bDk5LUNpYzRULXpTVVV0ZGp3T1VFeGc4SA?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQWjVfVWtRbW91aW80MW9BeEtHeXVIR2tLVEl1MG5iTFByRlcyU3BTSW1YZi1aXzNKSUpMOWMtWVlpaXNrZTd5T0RZcy1PRlZ0ZXNCNUJwd1JRekFDc2JDSFVrOThsQm5QeUZpYVpHQng0NkhoQ2pOSkdmcU1ZcC1BUTkxYUE3RmM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grifols S.A. (GRFS) Releases Q4 2025 Earnings: Revenue Up Strongly but EPS and Cash Flow Slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNVDN0TDZRVVdPWlpRSFdGVGZ4SDg0V3JmeHhTdHczRldsQ0txMHR5X0FZTlRRdGVhRkFCbVVYYUJBOUhwNDF3UU9RTHBnLXR3UWEzNmt4aERBak54amQtN1NfWmVhaUtxZTZ6MFA3YjdFTTA0YmRpcGtsRmJJbHFDTkItVTlsY3I2NWlfeF90TVFmcldGbkVSQjVWY0EtM2J4cWdVSExZVjdPSndEbFRLTW8yMkpXVGV0RUFYbXowdXhPeXg2Tm90S1NLMlIyUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 94, "total_relevant": 48, "sentiment_summary": {"positive": 13, "negative": 2, "neutral": 33, "score": 54, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.25, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 8.05, "count": 14}, {"event": "macro", "label": "Macro sensitivity", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 13, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 7.27, "latest_week": "2026-07-10", "one_week_move": 1.5, "four_week_move": -3.6, "twelve_week_move": -16.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.637814, "market_dynamics_buy_signal": false, "relative_strength": -30.264657, "fair_value_gap": -12.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.9907, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.5% over one week, -3.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 6}, {"label": "Ad-hoc-news.de", "count": 5}, {"label": "Finviz", "count": 5}, {"label": "DirectorsTalk Interviews", "count": 4}, {"label": "Seeking Alpha", "count": 4}, {"label": "ad-hoc-news.de", "count": 3}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 14}, {"label": "Macro sensitivity", "count": 4}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.5% over one week, -3.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Grifols stock steadies on its plasma business model"}], "updated_at": "2026-07-16T10:35:45.399901+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}